The Lombardi Comprehensive Cancer Center (Lombardi) participates in a wide range of innovative, feasibility, or proof-of- principle trials originating from its research programs. Enrollment in these studies has remained stable during the last grant period. The conduct of these studies is supported by research nursing and data management provided by the Clinical Research Management Office (CRMO). Research nursing focuses solely on the eligibility, consenting, and management of patients on clinical trials all of which is increasingly difficult in today's medical and regulatory environment In addition to its participation in the scope of high-priority clinical trials, Lombardi has conducted a series of innovative phase I trials of cancer vaccines and targeted agents that have provided important information on the mechanisms and clinical efficacy of these agents. These trials are among an extensive portfolio of phase I studies. The interaction of basic science and clinical programs has resulted in the testing of a series of agents that have been developed at Lombardi. The strong emphasis in translational research and drug development is reflected in the accomplishment of Lombardi investigators who have developed and brought to trial targeted agents, growth factor inhibitors, and radiation sensitizing agents. Lombardi continues to play a major role in the treatment and prevention of breast cancer. Selected, high priority clinical trials are given cancer center funding to support their execution. Such funds may come from the CCSG or from institutional sources. Regular Drug Discovery and Developmental Therapeutics (3DT) Program meetings include the presentation of new clinical trial concepts to a multidisciplinary group that includes 3DT members and members of other CCSG programs. The group prioritizes the trials, and the 3DT Program Leaders propose CCSG support to the Lombardi Director, who then assigns funds with the counsel of the Associate Directors and the Senior Operational Leadership Team.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-20
Application #
8739836
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-15
Project End
2014-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
20
Fiscal Year
2013
Total Cost
$35,708
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80
Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52
Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92
Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9

Showing the most recent 10 out of 544 publications